Shares of CSL (ASX:CSL) fell sharply on Monday after the Australian biopharmaceutical company cut its profit outlook for the year ending June 2026 and flagged material impairments over the next two fiscal years.
CSL slid 17.7% to A$98.59, marking a 9-1/2 year low, and was the largest drag on the ASX 200 index, which declined 1% on the session.
The company now expects net profit for the fiscal year to June 2026 at $3.1 billion, lower than last year’s $3.3 billion, and the revised figure represents a downgrade from its prior forecast for profit growth of between 4% and 7%.
On revenue, CSL forecast annual sales of $15.2 billion for fiscal 2026, a figure the company says is down from last year and below its earlier guidance that had anticipated 2% to 3% growth. The firm had reaffirmed its guidance in February before issuing the downgrade.
CSL announced it will recognise about $5 billion in non-cash impairments across fiscal 2026 and 2027. The impairment charge includes a major writedown related to its Vifor kidney treatment unit.
The company attributed both the guidance reduction and the impairment charges to tougher market conditions and to potential disruptions stemming from the Middle East conflict. Interim CEO Gordon Naylor communicated the downgrades on Monday and said an ongoing turnaround plan is taking longer than originally expected.
CSL’s share price has fallen almost 50% so far this year as the company faces sluggish demand for its influenza vaccine in its key U.S. market and mounting competition from generics.
Key points
- CSL cut fiscal 2026 net profit guidance to $3.1 billion, below last year’s $3.3 billion and down on prior forecasts of 4% to 7% profit growth.
- The company forecast revenue of $15.2 billion for the year to June 2026, a downgrade from expected 2% to 3% growth and lower than last year’s revenue.
- CSL will record approximately $5 billion of non-cash impairments across fiscal 2026-27, including a major writedown in the Vifor kidney treatment unit.
Risks and uncertainties
- Market risk - Tougher market conditions cited by the company may continue to pressure sales, particularly in the influenza vaccine segment and other key product lines.
- Geopolitical risk - CSL identified potential disruptions from the Middle East conflict as a factor contributing to the guidance cut and impairment decisions.
- Execution risk - Management says an internal turnaround plan is taking longer than expected, introducing uncertainty around the timing and effectiveness of remedial actions.
This report summarises the company’s updated financial expectations and the market reaction following the announcement. The information presented here is drawn from the company's statements and market moves disclosed on the day of the announcement.